BioCentury | Jun 27, 2016
Company News

Cipher, Edesa Biotech deal

...ASF-1096 has Orphan Drug designation in the EU to treat cutaneous lupus erythematosus. Last year, Astion Pharma A/S...
BioCentury | Mar 9, 2015
Company News

Astion, Cipher deal

...commercialize Dermadexin , Pruridexin and ASF-1096 . Dermadexin and Pruridexin are topical barrier-repair creams containing Astion’s...
...formulation of R-enantiomer of salbutamol (albuterol), is in Phase II testing for discoid lupus erythematosus. Astion...
...and is eligible for C$34 million ($27.2 million) in development, regulatory, commercialization and sales-based milestones. Astion Pharma A/S...
BioCentury | Jun 19, 2008
Cover Story

Moving Velcade into Lupus

...calcium modulator and cyclophilin ligand interactor (TACI) linked to Fc SLE; lupus nephritis Phase II/III Astion Pharma A/S...
BioCentury | May 15, 2008
Distillery Therapeutics

This Week in Therapeutics

...selective inhibitors of FAAH and MAGL and testing their efficacy as analgesics. Evotec AG and Astion Pharma A/S...
BioCentury | Feb 28, 2008
Distillery Therapeutics

This Week in Therapeutics

...for rat and recombinant human FAAH, respectively. The researchers did not disclose their next steps. Astion Pharma A/S's...
BioCentury | Jan 7, 2008
Clinical News

ASF-1096 regulatory update

...EMEA's Committee for Orphan Medical Products (COMP) granted Orphan Drug designation for Astion's ASF-1096 to treat...
...formulation of the R-enantiomer of salbutamol (albuterol) is in Phase IIb testing for the indication. Astion Pharma A/S...
BioCentury | Dec 17, 2007
Clinical News

ASF-1057: Phase III started

...to severe facial seborrheic dermatitis to compare topical ASF-1057 vs. 2% ketoconazole cream or placebo. Astion Pharma A/S...
BioCentury | Dec 17, 2007
Clinical News

ASF-1057: Phase III started

...moderate to severe facial seborrheic dermatitis to compare ASF-1057 vs. neutral moisturizing cream or placebo. Astion Pharma A/S...
BioCentury | Aug 6, 2007
Clinical News

ASF-1096 regulatory update

...for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Astion's...
...of lupus erythematosus. The 0.5% R-salbutamol cream is in Phase IIb testing for the indication. Astion Pharma A/S...
BioCentury | Apr 23, 2007
Company News

Astion board of directors update

Astion Pharma A/S , Copenhagen, Denmark Business: Inflammation, Dermatology Appointed: Flemming Ornskov, president and CEO of LifeCycle Pharma A/S , as chairman; and Flemming Pedersen, president and CEO of NeuroSearch A/S WIR Staff Dermatology Inflammation...
Items per page:
1 - 10 of 16
BioCentury | Jun 27, 2016
Company News

Cipher, Edesa Biotech deal

...ASF-1096 has Orphan Drug designation in the EU to treat cutaneous lupus erythematosus. Last year, Astion Pharma A/S...
BioCentury | Mar 9, 2015
Company News

Astion, Cipher deal

...commercialize Dermadexin , Pruridexin and ASF-1096 . Dermadexin and Pruridexin are topical barrier-repair creams containing Astion’s...
...formulation of R-enantiomer of salbutamol (albuterol), is in Phase II testing for discoid lupus erythematosus. Astion...
...and is eligible for C$34 million ($27.2 million) in development, regulatory, commercialization and sales-based milestones. Astion Pharma A/S...
BioCentury | Jun 19, 2008
Cover Story

Moving Velcade into Lupus

...calcium modulator and cyclophilin ligand interactor (TACI) linked to Fc SLE; lupus nephritis Phase II/III Astion Pharma A/S...
BioCentury | May 15, 2008
Distillery Therapeutics

This Week in Therapeutics

...selective inhibitors of FAAH and MAGL and testing their efficacy as analgesics. Evotec AG and Astion Pharma A/S...
BioCentury | Feb 28, 2008
Distillery Therapeutics

This Week in Therapeutics

...for rat and recombinant human FAAH, respectively. The researchers did not disclose their next steps. Astion Pharma A/S's...
BioCentury | Jan 7, 2008
Clinical News

ASF-1096 regulatory update

...EMEA's Committee for Orphan Medical Products (COMP) granted Orphan Drug designation for Astion's ASF-1096 to treat...
...formulation of the R-enantiomer of salbutamol (albuterol) is in Phase IIb testing for the indication. Astion Pharma A/S...
BioCentury | Dec 17, 2007
Clinical News

ASF-1057: Phase III started

...to severe facial seborrheic dermatitis to compare topical ASF-1057 vs. 2% ketoconazole cream or placebo. Astion Pharma A/S...
BioCentury | Dec 17, 2007
Clinical News

ASF-1057: Phase III started

...moderate to severe facial seborrheic dermatitis to compare ASF-1057 vs. neutral moisturizing cream or placebo. Astion Pharma A/S...
BioCentury | Aug 6, 2007
Clinical News

ASF-1096 regulatory update

...for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Astion's...
...of lupus erythematosus. The 0.5% R-salbutamol cream is in Phase IIb testing for the indication. Astion Pharma A/S...
BioCentury | Apr 23, 2007
Company News

Astion board of directors update

Astion Pharma A/S , Copenhagen, Denmark Business: Inflammation, Dermatology Appointed: Flemming Ornskov, president and CEO of LifeCycle Pharma A/S , as chairman; and Flemming Pedersen, president and CEO of NeuroSearch A/S WIR Staff Dermatology Inflammation...
Items per page:
1 - 10 of 16